Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

  • Andrew Spencer
  • , Suzanne Lentzsch
  • , Katja Weisel
  • , Hervé Avet-Loiseau
  • , Tomer M. Mark
  • , Ivan Spicka
  • , Tamas Masszi
  • , Birgitta Lauri
  • , Mark David Levin
  • , Alberto Bosi
  • , Vania Hungria
  • , Michele Cavo
  • , Je Jung Lee
  • , Ajay K. Nooka
  • , Hang Quach
  • , Cindy Lee
  • , Wolney Barreto
  • , Paolo Corradini
  • , Chang Ki Min
  • , Emma C. Scott
    • Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae Cheol Jo, Ho Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria Victoria Mateos

Research output: Contribution to journal › Article › peer-review

237 Scopus citations

Fingerprint

Dive into the research topics of 'Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science